I got shot down on my previous post due due TTF being presented:
Magrit
Re: None
Thursday, 11/03/2022 4:16:07 PM
I noticed these additional presentations at SNO:
Independent Supported Sessions at SNO
27th Annual Meeting and Education Day of the Society for Neuro-Oncology
November 16 - 20, 2022
Date: Wednesday, November 16, 2022
Time: 8:00AM – 4:30PM
Therapeutic Development in NeuroOncology Symposium
Location: Ballroom C, Tampa Convention Center
Symposium Chairs: Michael Vogelbaum MD, PhD and Peter Forsyth MD – Moffitt Cancer Center, Tampa, Florida
Speakers: For a full list of all of the speakers, click here.
On the list of speakers is:
Timothy Cloughesy
Professor of Neurology and Molecular and Medical Pharmacology
UCLA Health
In addition Dr. Stephen Brem will be speaking as well:
Date: Thursday, November 17, 2022
Time: 5:30PM – 7:30PM
Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care with Tumor Treating Fields and Other Innovative Approaches
Location: Ballroom D, Tampa Convention Center
Speakers:
Steven Brem, MD - Penn Brain Tumor Center, Philadelphia, Pennsylvania
Manmeet Ahluwalia, MD, MBA - Miami Cancer Institute, Miami, Florida
Suriya Jeyapalan, MD, MPH - Tufts Medical Center, Boston, Massachusetts
Innovative science is poised to transform glioblastoma management by offering the opportunity to enhance conventional management through the use of newer modalities, including tumor treating fields (TTFields) and efficacious systemic therapies. These novel options have been incorporated into clinical practice guidelines and are driving improved outcomes for patients with newly diagnosed and recurrent disease. The current challenge is how best to use these modalities in sequential combination strategies across glioblastoma treatment settings.
In a new “Seminars & Practicum” event, expert panelists will link current science to practical decisions that can help clinicians “set their sights” on achieving improved outcomes in glioblastoma. Throughout the lecture and case-based segments, the experts will provide context for the real-world impact of glioblastoma, focus on the latest data on TTFields, discuss TTFields delivery considerations, and address the integration of targeted and biomarker-guided therapies into glioblastoma management. This program will also feature patient perspectives,
Looking forward to DCVax being available to those suffering from cancer.
Margaret
